{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:20:35Z","timestamp":1790252435063,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40265-024-01997-7","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T21:02:35Z","timestamp":1708635755000},"page":"247-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Etrasimod: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"issue":"12","key":"1997_CR1","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1021\/ml500389m","volume":"5","author":"DJ Buzard","year":"2014","unstructured":"Buzard DJ, Kim SH, Lopez L, et al. Discovery of APD334: design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor. ACS Med Chem Lett. 2014;5(12):1313\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"1997_CR2","unstructured":"US FDA. VELSIPITY\u2122 (etrasimod) tablets, for oral use: US prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216956s000lbl.pdf. Accessed 11 Jan 2024."},{"issue":"1","key":"1997_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1242\/dev.094805","volume":"141","author":"K Mendelson","year":"2014","unstructured":"Mendelson K, Evans T, Hla T. Sphingosine 1-phosphate signalling. Development. 2014;141(1):5\u20139.","journal-title":"Development"},{"key":"1997_CR4","unstructured":"US FDA. VELSIPITY\u2122 (etrasimod) tablets, for oral use: NDA approval. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/216956Orig1s000ltr.pdf. Accessed 11 Jan 2024."},{"issue":"6 Suppl","key":"1997_CR5","doi-asserted-by":"publisher","first-page":"S-1095","DOI":"10.1016\/S0016-5085(23)03540-0","volume":"164","author":"B Siegmund","year":"2023","unstructured":"Siegmund B, Kiyomi K, Abreu M, et al. Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials [abstract no. Tu1724 plus poster]. Gastroenterology. 2023;164(6 Suppl):S-1095.","journal-title":"Gastroenterology"},{"key":"1997_CR6","unstructured":"European Medicines Agency. Summary of opinion (initial authorisation) - Velsipity (etrasimod). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-velsipity_en.pdf. Accessed 11 Jan 2024."},{"key":"1997_CR7","unstructured":"Pfizer. Pfizer completes acquisition of Arena Pharmaceuticals [media release]. 2022. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-completes-acquisition-arena-pharmaceuticals. Accessed 11 Jan 2024."},{"key":"1997_CR8","unstructured":"Everest Medicines. Everest Medicines achieved first patient dosing milestone in etrasimod phase 3 clinical study in ulcerative colitis patients in Asia [media release]. 2019. https:\/\/www.everestmedicines.com\/news\/everest-medicines-announces-completion-of-patient-enrollment-in-phase-3-clinical-trial-of-etrasimod-in\/63cf7489-0bdc-415b-8981-a531f9cbf5e2\/. Accessed 11 Jan 2024."},{"issue":"10383","key":"1997_CR9","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159\u201371.","journal-title":"Lancet"},{"issue":"6","key":"1997_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/cpdd.1255","volume":"12","author":"CA Lee","year":"2023","unstructured":"Lee CA, Oh DA, Tang Y, et al. Disposition and mass balance of etrasimod in healthy subjects and in vitro determination of the enzymes responsible for its oxidative metabolism. Clin Pharmacol Drug Dev. 2023;12(6):553\u201371.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"Suppl_1","key":"1997_CR11","doi-asserted-by":"publisher","first-page":"i029","DOI":"10.1093\/ecco-jcc\/jjab232.026","volume":"16","author":"C Lee","year":"2022","unstructured":"Lee C, Ramaiya A, Tang Y, et al. A phase 1 study evaluating the bioequivalence of the proposed commercial and clinical formulations of etrasimod 2mg, and the effect of food on the pharmacokinetics of the proposed commercial formulation in healthy volunteers [abstract no. OP27]. J Crohns Colitis. 2022;16(Suppl_1):i029.","journal-title":"J Crohns Colitis"},{"issue":"Suppl_1","key":"1997_CR12","doi-asserted-by":"publisher","first-page":"S321","DOI":"10.1093\/ecco-jcc\/jjab076.415","volume":"15","author":"C Lee","year":"2021","unstructured":"Lee C, Tang Y, Schroeder C, et al. Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study [abstract no. P291]. J Crohns Colitis. 2021;15(Suppl_1):S321\u20132.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"1997_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550\u201361.","journal-title":"Gastroenterology"},{"issue":"6","key":"1997_CR14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","volume":"15","author":"S Vermeire","year":"2021","unstructured":"Vermeire S, Chiorean M, Pan\u00e9s J, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohns Colitis. 2021;15(6):950\u20139.","journal-title":"J Crohns Colitis"},{"issue":"Suppl_1","key":"1997_CR15","doi-asserted-by":"publisher","first-page":"i764","DOI":"10.1093\/ecco-jcc\/jjac190.0762","volume":"17","author":"G D'Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky MC, Peyrin-Biroulet L, et al. Etrasimod induction therapy in moderately to severely active Crohn\u2019s disease: results from a phase 2, randomised, double-blind substudy [abstract no. P632]. J Crohns Colitis. 2023;17(Suppl_1):i764\u20135.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"1997_CR16","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/jdv.18914","volume":"37","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Bissonnette R, Kircik L, et al. Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE). J Eur Acad Dermatol Venereol. 2023;37(7):1366\u201374.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1997_CR17","first-page":"E128","volume":"187","author":"E Guttman-Yassky","year":"2022","unstructured":"Guttman-Yassky E, Bissonette R, Kircik L, et al. Long-term efficacy and safety of etrasimod, an oral, selective sphingosine 1-phosphate receptor1,4,5 modulator, for moderate-to-severe atopic dermatitis: results from the open-label extension of the phase II ADVISE study [abstract no. 245 plus presentation]. Br J Dermatol. 2022;187(3):E128\u20139.","journal-title":"Br J Dermatol"},{"issue":"Suppl_1","key":"1997_CR18","doi-asserted-by":"publisher","first-page":"i619","DOI":"10.1093\/ecco-jcc\/jjac190.0620","volume":"17","author":"S Vermeire","year":"2023","unstructured":"Vermeire S, Peyrin-Biroulet L, Pan\u00e9s J, et al. Etrasimod for the treatment of ulcerative colitis: up to 25 years of pooled safety data from global clinical trials [abstract no. P490 plus presentation]. J Crohns Colitis. 2023;17(Suppl_1):i619\u201320.","journal-title":"J Crohns Colitis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-01997-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-01997-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-01997-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T02:37:14Z","timestamp":1711766234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-01997-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1997"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-01997-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"23 February 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}